Know Cancer

or
forgot password

Histopathologic Evaluation of High Grade Brain Tumors by High Order Diffusion Tensor Imaging: Peritumoral Glial Cell Infiltration Quantitative Method


N/A
18 Years
85 Years
Open (Enrolling)
Both
High Grade Brain Tumor

Thank you

Trial Information

Histopathologic Evaluation of High Grade Brain Tumors by High Order Diffusion Tensor Imaging: Peritumoral Glial Cell Infiltration Quantitative Method


Patients with high grade brain tumor undergo a usual brain tumor MRI protocol as well as a
20 or 60 directions DT-MRI sequence upon patient collaboration. Images are acquired using a
3 Tesla MRI scanner (GE MR750 Discovery).

The usual brain tumor MRI protocol contains the following sequences: 3DT1, Axial T2, Flair,
T2 EG, diffusion (b0-b1000), 3DT1CE.

They will then undergo stereotactic tumor biopsies with Leksell frame mounted.

Biopsy targets will be surgically planned. The coordinates of this first biopsy will be
recorded for later coregistration with DT-MRI datasets.

Histopathologic analysis of the biopsies will be done using usual procedure. various
immunologic markers such as MAP2, Ki67 will be used on the first biopsy sample in order to
estimate the percentage of infiltration (ratio of tumor cells number over total cells
number).

Analysis of DT-MRI datasets will be done using home-made software for high order tensor
resolution and GA estimation at the exact coordinates of the biopsy sites.

Finally a statistical analysis (Pearson or Spearman) will be done to correlate GA and the
infiltration percentage.


Inclusion Criteria:



- Patients with high grade brain tumor

- Age greater than 18 yo and under 85 yo

- Signed informed consent from patient

Exclusion Criteria:

- -Any person with pacemaker, metal implant, claustrophobia, or any other
contraindication for MR examination

- Severe renal failure

- Brain tumor biopsy contraindication

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening

Outcome Measure:

DTI-MRI

Outcome Time Frame:

at J0

Safety Issue:

Yes

Principal Investigator

Betty JEAN

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Hospital, Clermont-Ferrand

Authority:

France: Ministry of Health

Study ID:

CHU-0125

NCT ID:

NCT01699269

Start Date:

April 2012

Completion Date:

April 2013

Related Keywords:

  • High Grade Brain Tumor
  • High grade brain tumor
  • Glioma
  • Glioblastoma Multiform
  • Brain Cancer
  • Diffusion-Weighted Magnetic Resonance Imaging
  • High order diffusion tensor
  • Imaging guided biopsy
  • Histopathologic evaluation
  • Infiltration percentage
  • Brain Neoplasms

Name

Location